

Q&A ITB-IDA/GDF – FLD/2019/001 - 20 December 2018

Q1: Clause 3.7.4. If a new supplier has not supplied any quantity in previous awarded tender, will the supplier be still considered a new supplier? For clarity, the supplies did not happen because orders were not placed.

A1: *If the supplier has signed the LTA for that product but didn't supply in the LTA period as no PO is received then it will not be considered as new supplier provided the quality status is in line with the ITB section 2.4.3.*

Q2: Clause 3.2.1. Bidder should ensure that PDF documents are high resolution and easily readable. Could you please confirm how many transmissions are allowed and size (in MB) per transmission will be allowed on servers?

A2: *IDA can receive attachments with a size of maximum 25 MB per e-mail.*

Q3: Clause 2.2.2 Could you please advise on timeline for implementation of GS1 Standards

A3: *GS1 implementation is scheduled for 2019. Further details on exact timelines and guidance will be provided by IDA after awarding and conclusion of LTAs.*

Q4: Clause 3.1.5.2. Advise if additional discounts are applicable for high-volume purchases. In comparison to last year tender there was staircase pricing based on stated volumes (in financial bid). Could you please confirm if the high quantity volume mentioned in "Annex A1 - Technical SLD Bid Response Form 2019" should be considered for discounts. Please confirm.

A4: *Discounts can be offered based on the volumes stated in Annex A1.*

Q5: Under clause number 3.7.4- technical evaluation criteria, it is mentioned that points would be awarded to the suppliers using two or more API sources in their formulations. Considering the scenario today of API shortages leading to supply delays, will additional points be allocated for those companies who manufacture their own API to be used in the formulations **(backwardly integrated)**.

A5: *No additional points will be allocated if API sources are in-house/backwardly integrated.*

Q6: As prequalification of APIs as well as formulations ensure that the patient gets assured quality medicines, would additional points be allocated for companies using Pre-qualified APIs in the formulations versus non-Prequalified APIs in their formulations

A6: *No additional points will be allocated if API sources are WHO PQ approved.*

Q7: We have noted that the forecast for KIT A provided in Tender period 2019 is the same as that provided in Tender period 2018. However, the procurement of KIT A in the ongoing tender has far exceeded the projected quantities. We request you to revisit the KIT A forecast and confirm the forecasted quantities of KIT A since it is essential for production capacity planning

A7: *These estimates are shown in Annex H: Indicative non-binding estimated quantities of this ITB document as per best current knowledge as stated in clause 2.3.2.*
